NervGen to Host Inaugural R&D Day on September 30, 2026
VANCOUVER, British Columbia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that it will host its inaugural R&D Day webcast on Wednesday, September 30, 2026, from 10:00 a.m. to 12:00 p.m. ET.
The event will provide an in-depth review of the NVG-291 program, spanning the scientific rationale and breadth of nonclinical and translational evidence supporting its development in SCI while highlighting the broader therapeutic potential; clinical data from the Phase 1 program and Phase 1b/2a CONNECT SCI study in individuals with chronic cervical SCI; and the design and rationale of RESTORE, the Company’s Phase 3 registrational study. Presentations will bring together scientific, clinical and community advocacy perspectives to provide broader context for the program, consider its relevance to the priorities and lived experiences of individuals with chronic cervical SCI, and provide greater detail on RESTORE’s study population and endpoint framework.
NervGen management will be joined by four leading experts whose work spans SCI clinical care, outcome assessment, translational research and community advocacy:
The presentations will be followed by a live question-and-answer session.
Webcast Information
To view a live webcast of the event, register here. A recording of the webcast will be available in the "Events & Presentations" section of NervGen’s website at www.nervgen.com.
About NervGen
NervGen (NASDAQ: NGEN) is a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. The Company’s mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. NervGen’s lead therapeutic candidate, NVG-291, is a subcutaneously administered, neuroreparative peptide designed to target the inhibitory CSPG-PTPσ pathway. NVG-291 is the first pharmacologic candidate to improve function, independence, and quality of life in chronic SCI, as observed in the Phase 1b/2a CONNECT SCI study. NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency for the treatment of SCI. Through NVG-291 and the Company’s next-generation candidate, NVG-300, NervGen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need. For more information, visit www.nervgen.com and follow NervGen on X and LinkedIn.
Contacts
On365 Partners, Investor Relations
ir@nervgen.com
203.293.8091
David Schull or Ignacio Guerrero-Ros, Ph.D., Media
Russo Partners
David.Schull@russopartnersllc.com
Ignacio.Guerrero-Ros@russopartnersllc.com
858.717.2310